LONDON—Europe’s medicines regulator has backed using AstraZeneca’s preventative COVID-19 therapy as a treatment for the disease and also endorsed another medicine as preventative option for another common virus. The regulator’s recommendations are usually followed by the European Commission when it takes a final decision on drug approvals. AstraZeneca said on Friday the European Medicines Agency…
EU Regulator Backs Wider Use of AstraZeneca COVID-19 Therapy
September 16, 2022
admin
AstrazenecaBusiness & MarketsCCP VirusCompaniesCOVID-19EuropehospitalizationsPUBLIC HEALTH INFORMATIONVaccinesVirusWorld
0 Comment
AstraZeneca Beats US Shareholder Lawsuit Over COVID-19 Vaccine Disclosures
NEW YORK—AstraZeneca Plc. on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States. U.S. District Judge Paul Oetken in Manhattan said AstraZeneca shareholders in the proposed class action failed to identify any…
Annual COVID-19 Boosters May Not Be Good Use of Resources: AstraZeneca Boss
Annual booster vaccination against COVID-19 may not be “a good use of resources,” the boss of major vaccine maker AstraZeneca has said. The UK health authorities are offering a booster jab to everyone over the age of 50 to protect them from COVID-19 and other respiratory diseases this winter. But Pascal Soriot, AstraZeneca’s chief executive…
AstraZeneca Lifts Revenue Guidance on COVID-19 Treatment
AstraZeneca said it expected prescriptions of its COVID-19 therapy to drive sales growth of more than 20 percent this year, as company reported second-quarter profit that topped analyst estimates. The injection, called Evusheld, which is designed to protect against COVID-19 infection for at least six months, has been deployed in many countries for people with…
AstraZeneca to Buy Oncology Firm TeneoTwo for Up to $1.27 Billion
AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc. in a deal worth up to $1.27 billion on Tuesday, in a move to bolster its roster of therapies to treat blood cancers. At the heart of the deal is the U.S.-based company’s early-stage experimental treatment for a form of Non-Hodgkin’s lymphoma, a type of cancer that…
Studies Suggest Possible Link of Neuromyelitis Optica Diagnosis After COVID-19 Vaccination
June 18, 2022
admin
AmericasAsia & PacificAstrazenecaBrightCCP VirusCovid NewsCOVID-19 VaccinesEuropehealthHealth NewsModernaPfizerUSUS NewsVaccines & SafetyWorld
0 Comment
Emergent peer-reviewed studies have highlighted the occurrence of neuromyelitis optica after COVID-19 vaccinations, suggesting that the autoimmune disease may be occurring as a vaccine adverse event. The studies’ general findings indicate an occurrence of neuromyelitis optica (NMO) in healthy individuals within around two weeks after Pfizer, Moderna, and AstraZeneca vaccines. In patients already affected by…
‘Significant’ Cases of Neurological Disorder Associated with the AstraZeneca Vaccine
May 31, 2022
admin
AMERICAAstrazenecaCCP VirusEditor's PicksGuillain-Barré syndromeInternationalUKVaccines & SafetyWorld
0 Comment
A UK study by University College London has confirmed “small but significant” cases of the serious Guillain-Barre syndrome (GBS), a rare neurological disorder associated with the AstraZeneca vaccine for COVID-19. The researchers speculate that the “the majority or all” of the 121 UK cases of GBS (pdf) in March to April 2021 were associated with first…
AstraZeneca Says Its COVID-19 Shot Still Has Role Despite Global Glut
AstraZeneca’s COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said on Friday, the latest drugmaker to warn about a global supply glut. The comments come after the company reported better-than-expected first-quarter profit and sales…
AstraZeneca Predicts Revenue Hit as Demand for COVID-19 Vaccines Falls
Anglo-Swedish pharmaceutical giant AstraZeneca said that it expects the revenue from its COVID-19 vaccines to decline by up to a quarter this year as demand wanes for the product. Announcing its results for the first quarter of 2022, the firm said the sales of Vaxzevria—more commonly known as the Oxford/AstraZeneca vaccine—is expected to decline later…
MP Says Vaccine Manufacturer Not Answering ‘Basic Questions’ on Why Liability Clauses Were Requested
A Conservative MP says the president of the Canadian arm of AstraZeneca couldn’t answer questions at a parliamentary committee as to why the company asked for clauses to be shielded from liability for vaccine-related injuries. “‘Indemnification clauses’ protect manufacturers of #vaccines from liability. Today at the Foreign Affairs Committee the President of @AstraZenecaCA could not…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`